Scott Friedman
Gastroenterology · New York, NYNPI 1184656209
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $185,516 of the $256,142 with a category attached, or 72.4%. 22 manufacturers reported payments, led by Pfizer at 32.7% of the total. Reporting peaked in 2024 at $87,261 and has fallen 73.6% since, to $23,007 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $2032.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$84K
- Incyte Corporation$43K
- Novo Nordisk$29K
- Boehringer Ingelheim$29K
- Merck$27K
- Gilead$10K
- plus $34K from 16 others
Across 4 payments — averaging $306,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.2M
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Consulting fees$185,51672%
- Speaking & faculty fees$15,5896%
- Travel & lodging$9,6104%
- Food & beverage$2,6601%
- Other$42,76817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 35 | $83,670 |
| Incyte Corporation | 1 | $42,768 |
| Novo Nordisk | 8 | $29,277 |
| Boehringer Ingelheim | 26 | $29,272 |
| Merck | 19 | $27,030 |
| Gilead | 6 | $10,137 |
| Regeneron | 3 | $6,808 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $6,072 |
| Boehringer Ingelheim International GmbH | 1 | $4,410 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,000 |
| Alnylam Pharmaceuticals Inc. | 1 | $3,375 |
| Amgen | 1 | $2,616 |
| Theratechnologies Inc. | 2 | $2,018 |
| Idorsia Pharmaceuticals US Inc | 2 | $1,620 |
| Eisai Inc. | 1 | $1,500 |
| Intercept Pharmaceuticals, Inc. | 2 | $461 |
| AbbVie | 1 | $450 |
| Madrigal Pharmaceuticals | 2 | $184 |
| Genentech, Inc. | 1 | $153 |
| Genentech USA, Inc. | 1 | $136 |
| GSK | 1 | $125 |
| Shionogi Inc | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$256,142 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.